Perry Stambolsky

1.3k citations
14 papers · 1.0k indexed · h-index 11
Topics
Cancer-related Molecular Pathways (9 papers)Epigenetics and DNA Methylation (3 papers)RNA Interference and Gene Delivery (3 papers)
Partner nations
IsraelFranceMali

In The Last Decade

Perry Stambolsky

14 papers receiving 999 citations

Peers

Perry Stambolsky
Comparison fields: 5 of 78
  • Molecular Biology 700
  • Oncology 588
  • Cancer Research 272
  • Biotechnology 134
  • Pathology and Forensic Medicine 108
Replace Irit Zurer with:
Irit Zurer Israel
L. Jayaraman United States
H U Kontny United States
Kevin P. Rice United States
M. Gloria Luciani United Kingdom
Ira Kogan-Sakin Israel
Deug Y. Shin South Korea
Jiangxue Wu China
Barbara Cecchinelli Italy
Richard A. Woo Canada
Perry Stambolsky relative to Irit Zurer Israel Irit Zurer's profile →
Citations per field
00.5×3.8×
Irit Zurer · 1×
Citations per year

Countries citing papers authored by Perry Stambolsky

Since Specialization
Citations

This map shows the geographic impact of Perry Stambolsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Perry Stambolsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Perry Stambolsky more than expected).

Fields of papers citing papers by Perry Stambolsky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Perry Stambolsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Perry Stambolsky. The network helps show where Perry Stambolsky may publish in the future.

Co-authorship network of co-authors of Perry Stambolsky

This figure shows the co-authorship network connecting the top 25 collaborators of Perry Stambolsky. A scholar is included among the top collaborators of Perry Stambolsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Perry Stambolsky. Perry Stambolsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
#WorkIndexed citations
1 93
2 3
3 33
4 196
5 130
6 7
7 4
8 68
9 31
10 169
11 48
12 119
13 14
14 105

About Perry Stambolsky

Perry Stambolsky is a scholar working on Oncology, Molecular Biology and Cancer Research, having authored 14 papers that have together received 1.0k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (9 papers), Epigenetics and DNA Methylation (3 papers) and RNA Interference and Gene Delivery (3 papers). The work is most often cited by research in Oncology (588 citations), Cancer Research (272 citations) and Biotechnology (134 citations). Perry Stambolsky has collaborated with scholars based in Israel, France and Mali. Frequent co-authors include Varda Rotter, Lilach Weisz, Moshe Oren, Naomi Goldfinger, Igor Shats, Eyal Kalo, Ira Kogan, Yuval Tabach, Amir Zalcenstein and Giulia Fontemaggi. Their work appears in journals such as Journal of Biological Chemistry, Molecular and Cellular Biology and Cancer Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026